Last reviewed · How we verify
NCT03411876: IPF/Oxymizer2
Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis
NA trial testing Oxymizer® pendant nasal cannula in Idiopathic Pulmonary Fibrosis in 22 participants. Completed in 15 January 2019.
15 January 2019
Quick facts
| Lead sponsor | Klaus Kenn |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 18 January 2018 |
| Primary completion | 15 January 2019 |
| Estimated completion | 15 January 2019 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Oxymizer® pendant nasal cannula
- conventional nasal cannula
Conditions studied
- Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →
- Hypoxemia — all drugs for Hypoxemia →
Sponsor
Klaus Kenn
Who can join
Eligibility, any sex, with Idiopathic Pulmonary Fibrosis or Hypoxemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim of this study is to investigate the effects of an Oxymizer pendant nasal cannula in hypoxemic patients with idiopathic pulmonary fibrosis during walking.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Acute effects of supplemental oxygen therapy using different nasal cannulas on walking capacity in patients with idiopathic pulmonary fibrosis: a randomised crossover trial.
Schneeberger T, Leitl D, Gloeckl R, Jarosch I, et al · · 2020 · cited 1× · PMID 32832533 · DOI 10.1183/23120541.00197-2020
Verify or expand the search:
- PubMed search for NCT03411876
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Idiopathic Pulmonary Fibrosis
Currently open trials in the same condition.
- NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
- NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
- NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
- NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
- NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting
Other Klaus Kenn trials
Trials by the same sponsor.
- NCT04363723 — The Influence of an Acute Exacerbation During Pulmonary Rehabilitation in COPD Patients Awaiting Lung Transplantation · completed
- NCT04184180 — Effects of Inpatient Pulmonary Rehabilitation on Frailty in Patients After Lung-Transplantation · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03411876 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Klaus Kenn
- Last refreshed: 16 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03411876.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing